Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: J Heart Lung Transplant. 2015 Oct 19;35(3):342–351. doi: 10.1016/j.healun.2015.10.019

Table 2.

Selected pharmacotherapies for controls and heart failure with reduced left ventricular ejection fraction (HFrEF) patients

Controls (%) HFrEF (%)
Loop or thiazide diuretic 3 (17) 34 (81)
β-receptor antagonist 3 (17) 30 (71)
Aspirin 5 (28) 27 (64)
ACE-inhibitor 2 (11) 21 (50)
Mineralocorticoid Receptor Antagonists 0 (0) 17 (40)
HMG-CoA Reductase Inhibitor
(Statin) 		2 (11) 17 (40)
ARB 1 (6) 8 (19)
Calcium channel antagonist 4 (22) 6 (14)
Non-statin lipid therapy 0 (0) 6 (12)
Nitroglycerin 0 (0) 5 (12)
Insulin 0 (0) 4 (10)
Metformin 0 (0) 2 (5)
Glitazone 0 (0) 1 (2)

Pharmacotherapy data was collected from HFrEF patients (N=42) or unexplained dyspnea (controls)(N=18) referred for invasive cardiopulmonary exercise testing. ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker.